DMC: Subsequent Close of Series B Financing, Total Raised $39 million

DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million.

DMC previously announced the first close of its Series B fundraising on 2 December 2021 with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “The addition of these strategic investors who have domain experience in nutrition and biobased chemicals, respectively, further enhances our opportunities to serve these market segments. We now have multiple strategic investors on board which validates our accomplishments to date and our potential. We are excited to continue growing the company to its next stage with the support of all of our stakeholders.”

DMC is commercial with its first product, a bio-based chemical intermediate with primary applications in sustainable detergents and human nutrition. DMC has a deep pipeline of predictable, scalable, and cost-competitive products that provide sustainable and economically attractive solutions for many industries, including animal nutrition, human nutrition, personal and home care, and biobased chemical intermediates.

DMC’s technology platform addresses the key barriers that have plagued the biotech industry for decades including standardization, robustness, and predictability across scale. Addressing these challenges translates to a dramatic reduction in the time to market and the investment needed to bring products to commercialization.

About DMC

DMC is a US bio-based chemical company that makes products using microbial fermentation. DMC’s proprietary technology platform simplifies the engineering of biology and makes fermentation more standardized, robust, and predictable.